Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... phylum so full of mean little creatures, the yellow-colored Ormia ... -- at least to crickets. Native to the southeastern U.S. ... sort of parasite. It swoops onto the back of a ... its wicked brood to invade, kill and consume the cricket ... possible without the fly,s ability to find a cricket -- ...
(Date:7/22/2014)... engineering at the University of Texas at Dallas, has ... Texas section of the American Society of Mechanical Engineers ... 158 countries who develop engineering standards and training. They ... the world. , ASME recognized Baughn earlier this year ... Baughn retired as an engineering fellow in 2012 after ...
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and ... and other markets, announced today that it has closed ... private investors led by Novit L.P., an investment arm ... involved the signing of a Securities Purchase Agreement under ... at a price per share of $1.00, resulting in ...
(Date:7/22/2014)... 22, 2014 The DNA Spectrum ... concise visual representation of history, migration, and culture. ... regaled by family history stories stemming from Europe. His ... "old country." Pictures and 8mm home movies painted an ... the family, and Steve ordered a test from DNA ...
Breaking Biology Technology:Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4UT Dallas professor receives Engineer of the Year award 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4
... Calif., May 28 CV Therapeutics,Inc. (Nasdaq: ... Nasdaq,marketplace rule 4350, the Company issued new inducement ... hiring, primarily in connection,with its commercialization efforts in ... cover an aggregate 151,800 shares of,common stock and ...
... with research institute to aid in successful mid-career changes, ... Center,( http://www.biocareercenter.com ) an online job board and careers ... Research,Institute who has developed Career Navigator -- a new ... within their fields with success --,to launch this new ...
... SoluLinK, Inc., a leader in,next-generation conjugation products ... of a new product, NanoLink(TM) Streptavidin Magnetic,Microspheres. ... of any commercially available polymer-encapsulated streptavidin,magnetic microsphere. ... throughput robotic applications where high biotin loads,must ...
Cached Biology Technology:CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2Online Career Service Turns Focus to 'Switching Gears' 2SoluLinK Introduces NanoLink(TM) Streptavidin Magnetic Microspheres 2
(Date:7/23/2014)... essential fatty acids and energy to infants and ... concern that soybean-based emulsions could compromise immune functions ... Combination lipid emulsions based on triglyceride oil, fish ... address this concern. , However, researchers at Rutgers ... unwarranted, according to a review published today in ...
(Date:7/22/2014)... The exhibit consists of both still images and ... of scientific research. Forty-four still images were chosen ... students, postdocs, staff, and alumni representing more than ... from more than 50 submissions. , Zach Donnell, ... of the 2014 organizers, noted that the exhibit ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2014. ... million, an increase of 53% compared to $4.4 million in ... income in the second quarter of 2014 was $1.4 million ... The increase in revenue and operating income was driven by ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... (NASDAQ: ABPI) announces evidence that most, if not all ... fungal-induced inflammation as originally proposed by investigators at the ... of the Companys ongoing pivotal Phase 3 clinical trial ... of the antifungal amphotericin B 0.01% suspension. In ...
... most renowned physicists and engineers, OSA,s Frontiers in Optics meeting ... developments in the science of light. What: Frontiers ... 16-20, 2007 Where: Fairmont Hotel, San Jose, Calif. ... A new device that may help give sight to the ...
... great flood of Noahs generation really occur thousands of years ... ancient tsunami" Will pollution levels in our deep seas remain ... of the questions that are being addressed by a new ... non-profit research and education organization, EcoOcean. The team, ...
Cached Biology News:SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma 2Frontiers in Optics presents scientific advancements 2TAU scientists probe 'deep' questions aboard EcoOcean's environmental research ship 2TAU scientists probe 'deep' questions aboard EcoOcean's environmental research ship 3
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... A simultaneous dual parameter assay ... poly caspase activity. Active caspases are ... peptide inhibitors, which are cell-permeable, non-cytotoxic ... caspases within the cells. At the ...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: